ATE194981T1 - Oxazolidinderivat und sein pharmazeutisch verträgliches salz - Google Patents
Oxazolidinderivat und sein pharmazeutisch verträgliches salzInfo
- Publication number
- ATE194981T1 ATE194981T1 AT93911946T AT93911946T ATE194981T1 AT E194981 T1 ATE194981 T1 AT E194981T1 AT 93911946 T AT93911946 T AT 93911946T AT 93911946 T AT93911946 T AT 93911946T AT E194981 T1 ATE194981 T1 AT E194981T1
- Authority
- AT
- Austria
- Prior art keywords
- represent
- alkyl
- alkylene
- optionally halogenated
- pharmaceutically acceptable
- Prior art date
Links
- 150000002917 oxazolidines Chemical class 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000002947 alkylene group Chemical group 0.000 abstract 3
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- -1 2-oxazolyl Chemical group 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11177392 | 1992-04-30 | ||
| PCT/JP1993/000559 WO1993022298A1 (fr) | 1992-04-30 | 1993-04-28 | Derive d'oxazolidine et son sel pharmaceutiquement acceptable |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE194981T1 true ATE194981T1 (de) | 2000-08-15 |
Family
ID=14569807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT93911946T ATE194981T1 (de) | 1992-04-30 | 1993-04-28 | Oxazolidinderivat und sein pharmazeutisch verträgliches salz |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5480899A (de) |
| EP (1) | EP0605729B1 (de) |
| KR (1) | KR0146931B1 (de) |
| AT (1) | ATE194981T1 (de) |
| AU (1) | AU653896B2 (de) |
| CA (1) | CA2112129C (de) |
| DE (1) | DE69329106T2 (de) |
| FI (1) | FI935920A7 (de) |
| HU (2) | HU220601B1 (de) |
| WO (1) | WO1993022298A1 (de) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU220601B1 (hu) * | 1992-04-30 | 2002-03-28 | Taiho Pharmaceutical Co. Ltd. | Fenoxi-alkil-oxazolidin-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények |
| HU0203995D0 (en) * | 1992-12-23 | 2003-04-28 | Bristol Myers Squibb Co | Oxazole derivatives for synthesis of sidechain-bearing taxanes and preparation thereof |
| TW268952B (de) * | 1993-02-26 | 1996-01-21 | Takeda Pharm Industry Co Ltd | |
| DE4332384A1 (de) * | 1993-09-23 | 1995-03-30 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten III |
| TW286317B (de) * | 1993-12-13 | 1996-09-21 | Hoffmann La Roche | |
| DE4408534A1 (de) * | 1994-03-14 | 1995-09-28 | Hoechst Ag | Substituierte N-Ethyl-Glycinderivate zur Herstellung von PNA und PNA-/DNA-Hybriden |
| DE4425612A1 (de) * | 1994-07-20 | 1996-04-04 | Bayer Ag | 6-gliedrige stickstoffhaltige Heteroaryl-oxazolidinone |
| ATE170179T1 (de) | 1994-11-02 | 1998-09-15 | Merck Patent Gmbh | Adhäsionsrezeptor-antagonisten |
| US6465650B1 (en) | 1995-03-13 | 2002-10-15 | Aventis Pharma Deutschland Gmbh | Substituted N-ethylglycine derivatives for preparing PNA and PNA/DNA hybrids |
| GB9812019D0 (en) * | 1998-06-05 | 1998-07-29 | Zeneca Ltd | Chemical compounds |
| EP1082323A2 (de) | 1998-06-05 | 2001-03-14 | AstraZeneca UK Limited | Oxazolidinon-derivate, verfahren zu ihrer herstellung und diese derivate enthaltende pharmazeutische zusammensetzungen |
| GB9928568D0 (en) | 1999-12-03 | 2000-02-02 | Zeneca Ltd | Chemical compounds |
| GB0009803D0 (en) * | 2000-04-25 | 2000-06-07 | Astrazeneca Ab | Chemical compounds |
| JP2004525109A (ja) | 2001-02-15 | 2004-08-19 | キング・ファーマシューティカルズ・インコーポレイティッド | 安定化された甲状腺ホルモン医薬組成物、及びその製法 |
| US7101569B2 (en) | 2001-08-14 | 2006-09-05 | Franz G Andrew | Methods of administering levothyroxine pharmaceutical compositions |
| DOP2005000123A (es) * | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | Inhibidores de cetp |
| WO2007081569A2 (en) * | 2005-12-30 | 2007-07-19 | Merck & Co., Inc. | Cetp inhibitors |
| JP5040036B2 (ja) | 2005-12-30 | 2012-10-03 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｃｅｔｐ阻害剤として有用な１，３−オキサゾリジン−２−オン誘導体 |
| US8835426B2 (en) * | 2007-02-26 | 2014-09-16 | Vitae Pharmaceuticals, Inc. | Cyclic urea and carbamate inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
| EP2141154A4 (de) * | 2007-03-30 | 2011-06-01 | Inst Med Molecular Design Inc | Oxazolidinonderivat mit hemmender wirkung auf die 11-hydroxysteroiddehydrogenase vom typ i |
| JP5451611B2 (ja) * | 2007-07-26 | 2014-03-26 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１のサイクリックインヒビター |
| AR069207A1 (es) * | 2007-11-07 | 2010-01-06 | Vitae Pharmaceuticals Inc | Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1 |
| CA2708303A1 (en) | 2007-12-11 | 2009-06-18 | Vitae Pharmaceuticals, Inc. | Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1 |
| TW200934490A (en) * | 2008-01-07 | 2009-08-16 | Vitae Pharmaceuticals Inc | Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1 |
| JP2011510083A (ja) * | 2008-01-24 | 2011-03-31 | メルク・シャープ・エンド・ドーム・コーポレイション | ３，５−二置換−１，３−オキサゾリジン−２−オン誘導体 |
| WO2009094169A1 (en) * | 2008-01-24 | 2009-07-30 | Vitae Pharmaceuticals, Inc. | Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| CA2714532A1 (en) * | 2008-02-11 | 2009-08-20 | Vitae Pharmaceuticals, Inc. | 1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1 |
| US8598160B2 (en) * | 2008-02-15 | 2013-12-03 | Vitae Pharmaceuticals, Inc. | Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| CA2718264A1 (en) * | 2008-03-18 | 2009-09-24 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 |
| CA2723032A1 (en) * | 2008-05-01 | 2009-11-05 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| TW201004945A (en) | 2008-05-01 | 2010-02-01 | Vitae Pharmaceuticals Inc | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| EP2291370B1 (de) | 2008-05-01 | 2013-11-27 | Vitae Pharmaceuticals, Inc. | Cyclische inhibitoren von 11beta-hydroxysteroiddehydrogenase 1 |
| KR20110002492A (ko) | 2008-05-01 | 2011-01-07 | 비타이 파마슈티컬즈, 인코포레이티드 | 11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제 |
| WO2010011314A1 (en) | 2008-07-25 | 2010-01-28 | Boehringer Ingelheim International Gmbh | Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1 |
| US8846668B2 (en) | 2008-07-25 | 2014-09-30 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| IES20090901A2 (en) * | 2008-11-28 | 2010-07-07 | Corden Pharma Ip Ltd | Manufacture of beta blockers |
| JP5679997B2 (ja) | 2009-02-04 | 2015-03-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤 |
| UA109255C2 (ru) | 2009-04-30 | 2015-08-10 | Берінгер Інгельхайм Інтернешнл Гмбх | Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1 |
| KR20120061771A (ko) * | 2009-04-30 | 2012-06-13 | 비타이 파마슈티컬즈, 인코포레이티드 | 11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제 |
| WO2011011123A1 (en) | 2009-06-11 | 2011-01-27 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure |
| WO2011002910A1 (en) | 2009-07-01 | 2011-01-06 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| EP2582698B1 (de) | 2010-06-16 | 2016-09-14 | Vitae Pharmaceuticals, Inc. | Substituierte 5-,6- und 7-gliedrige heterocyclen, medikamente mit derartigen verbindungen und ihre verwendung |
| WO2011161128A1 (en) | 2010-06-25 | 2011-12-29 | Boehringer Ingelheim International Gmbh | Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders |
| CA2813671A1 (en) | 2010-11-02 | 2012-05-10 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations for the treatment of metabolic disorders |
| EP3445753A1 (de) * | 2016-04-22 | 2019-02-27 | Kat2Biz AB | Difunktionelles pfropfmittel auf der basis von phenolischem rückgrat aus lignin |
| AR111295A1 (es) | 2017-03-20 | 2019-06-26 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) |
| WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| US20200129485A1 (en) | 2018-09-19 | 2020-04-30 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| MX2022003025A (es) | 2019-09-19 | 2022-04-07 | Forma Therapeutics Inc | Activacion de la piruvato cinasa r. |
| WO2022075645A1 (ko) * | 2020-10-08 | 2022-04-14 | 재단법인 대구경북첨단의료산업진흥재단 | Pcsk9 억제제로서 아미노알콜 유도체 및 이를 함유하는 고콜레스테롤 혈증의 예방 또는 치료용 약학적 조성물 |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3020262A (en) * | 1957-12-19 | 1962-02-06 | Jefferson Chem Co Inc | Method for producing 2-oxazolidones from epoxides and isocyanates |
| DE3205457A1 (de) * | 1982-02-16 | 1983-08-25 | Merck Patent Gmbh, 6100 Darmstadt | Oxazolidin-2-one |
| US4602093A (en) * | 1984-02-08 | 1986-07-22 | Merck & Co., Inc. | Novel substituted imidazoles, their preparation and use |
| KR970006890B1 (ko) * | 1987-10-20 | 1997-04-30 | 오스카 세이야꾸 가부시끼가이샤 | 페닐카르복시산 유도체 및 그 염 |
| CA1330079C (en) * | 1988-10-13 | 1994-06-07 | Michihiko Tsujitani | Pyrrolo (3,2-e)pyrazolo(1,5-a)pyrimidine derivative and medicine comprising the same |
| DK0393607T3 (da) * | 1989-04-19 | 1996-03-18 | Otsuka Pharma Co Ltd | Phenylcarboxylsyrederivater med en heteroring |
| HU220601B1 (hu) * | 1992-04-30 | 2002-03-28 | Taiho Pharmaceutical Co. Ltd. | Fenoxi-alkil-oxazolidin-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények |
-
1993
- 1993-04-28 HU HU9303787A patent/HU220601B1/hu not_active IP Right Cessation
- 1993-04-28 CA CA002112129A patent/CA2112129C/en not_active Expired - Fee Related
- 1993-04-28 WO PCT/JP1993/000559 patent/WO1993022298A1/ja not_active Ceased
- 1993-04-28 AT AT93911946T patent/ATE194981T1/de not_active IP Right Cessation
- 1993-04-28 DE DE69329106T patent/DE69329106T2/de not_active Expired - Fee Related
- 1993-04-28 FI FI935920A patent/FI935920A7/fi not_active IP Right Cessation
- 1993-04-28 KR KR1019930704109A patent/KR0146931B1/ko not_active Expired - Fee Related
- 1993-04-28 US US08/167,798 patent/US5480899A/en not_active Expired - Fee Related
- 1993-04-28 EP EP93911946A patent/EP0605729B1/de not_active Expired - Lifetime
- 1993-04-28 AU AU42710/93A patent/AU653896B2/en not_active Ceased
-
1995
- 1995-06-30 HU HU95P/P00726P patent/HU211901A9/hu unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR940701389A (ko) | 1994-05-28 |
| CA2112129A1 (en) | 1993-11-11 |
| CA2112129C (en) | 1997-10-07 |
| DE69329106T2 (de) | 2001-03-22 |
| EP0605729A4 (en) | 1994-08-24 |
| EP0605729A1 (de) | 1994-07-13 |
| DE69329106D1 (de) | 2000-08-31 |
| FI935920L (fi) | 1993-12-29 |
| EP0605729B1 (de) | 2000-07-26 |
| AU4271093A (en) | 1993-11-29 |
| AU653896B2 (en) | 1994-10-13 |
| US5480899A (en) | 1996-01-02 |
| HUT70423A (en) | 1995-10-30 |
| HU220601B1 (hu) | 2002-03-28 |
| KR0146931B1 (ko) | 1998-08-17 |
| WO1993022298A1 (fr) | 1993-11-11 |
| HU211901A9 (en) | 1996-01-29 |
| FI935920A0 (fi) | 1993-12-29 |
| FI935920A7 (fi) | 1993-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69329106D1 (de) | Oxazolidinderivat und sein pharmazeutisch verträgliches salz | |
| FI932445A0 (fi) | Farmaceutiska foereningar | |
| PT94160A (pt) | Processo para preparacao de derivados de alfa-aminocarboxamidas n-fenilalquil substituidas e composicoes farmaceuticas que os contem | |
| MA20770A1 (fr) | Nouveaux acides quinolone-carboxyliques substitues a substituant diazabicycloalkyle ponte | |
| NZ238181A (en) | N-(1-substituted-piperidinyl(alkyl))carbamic acid, urea and carboxamide derivatives and homologues thereof; preparatory processes and pharmaceutical compositions | |
| EP0495776A4 (de) | Stabilisierte komplexe bestehend aus stickoxyd/primäre amine zur verwendung als kardiovaskuläre wirkstoffe. | |
| PT91602A (pt) | Processo para a preparacao de compostos espiro com accao antibacteriana e de composicoes farmaceuticas que os contem | |
| DE69423139D1 (de) | Amid-Derivate mit anti-hypercholesterolemischer Wirkung, deren Herstellung und deren Verwendungen als Heilmittel | |
| NO302755B1 (no) | Morfinan-derivater | |
| ATE146473T1 (de) | Pyrazolopyridinverbindungen und verfahren zu ihrer herstellung | |
| ATE194828T1 (de) | Entzündungshemmendes und analgetisches äusserliches pflaster-präparat | |
| ATE192446T1 (de) | Kondensierte benzoxa-ringverbindung, deren herstellung sowie diese enthaltendes arzneimittel | |
| TW206970B (de) | ||
| ES2055077T3 (es) | Un procedimiento para preparar derivados de amida de acido carboxilico. | |
| NO891350L (no) | Acylderivater. | |
| MX9200777A (es) | 4-[(2-benzotiazolil)metilamino]-alfa-[(3,4-difluorofenoxi)metil]-1-pip eridetanol. | |
| NO924758L (no) | Nye amidinoaftylfurankarboksylatderivater og syreaddisjonssalter derav | |
| HUT64318A (en) | Process for production benzodpyrane derivativs and pharmaceutical preparations containing these compounds as effective substance | |
| ATE171704T1 (de) | Optisch wirksame alkylendioxybenzolderivate und ihre verwendung als arzneimittel | |
| ATE128131T1 (de) | Substituierte pyridinsulfonamide oder deren salze, verfahren zur herstellung und diese enthaltende herbizide. | |
| DE69017839D1 (de) | NMDA-blockierende Verbindungen, pharmazeutische Präparate, deren Herstellung und Verwendung. | |
| ATE172959T1 (de) | Acylphenylglycin-derivat und dieses als aktivbestandteil enthaltendes vorbeugungs -und heilmittel gegen durch erhöhte collagenaseaktivität verursachte krankheiten | |
| ES2037004T3 (es) | Metodo para producir un compuesto relacionado con el antibiotico tan-749. | |
| SE9201188D0 (sv) | Ny anvaendning | |
| DE69011174D1 (de) | Catecholaminester. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |